Evidence map›Paper›PMID 35744740›Full record

ArticleMicroorganisms2022

PDIA, an Iminosugar Compound with a Wide Biofilm Inhibitory Spectrum Covering Both Gram-Positive and Gram-Negative Human Bacterial Pathogens.

Łucja Kozień, Estelle Gallienne, Olivier Martin, Sophie Front, Magdalena Strus, Piotr Heczko

Open access · goldAbstract read
In one paragraph

Article in Microorganisms, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Frontiers in microbiology · 2026
    Article
  2. A rational approach to discovering new persister control agents.Antimicrobial agents and chemotherapy · 2025
    Article
  3. Article
  4. Article
  5. PDIA iminosugar influence on subcutaneousFrontiers in cellular and infection microbiology · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Łucja KozieńDepartment of Bacteriology, Microbial Ecology and Parasitology, Chair of Microbiology, Jagiellonian University Medical College, 31-121 Cracow, Poland.ORCID 0000-0002-4831-4549
Estelle GallienneInstitut de Chimie Organique et Analytique (ICOA), UMR 7311, Université d'Orléans & CNRS, rue de Chartres, BP 6759, CEDEX 2, 45067 Orléans, France.
Olivier MartinInstitut de Chimie Organique et Analytique (ICOA), UMR 7311, Université d'Orléans & CNRS, rue de Chartres, BP 6759, CEDEX 2, 45067 Orléans, France.
Sophie FrontInstitut de Chimie Organique et Analytique (ICOA), UMR 7311, Université d'Orléans & CNRS, rue de Chartres, BP 6759, CEDEX 2, 45067 Orléans, France.
Magdalena StrusDepartment of Bacteriology, Microbial Ecology and Parasitology, Chair of Microbiology, Jagiellonian University Medical College, 31-121 Cracow, Poland.ORCID 0000-0002-7437-5230
Piotr HeczkoDepartment of Bacteriology, Microbial Ecology and Parasitology, Chair of Microbiology, Jagiellonian University Medical College, 31-121 Cracow, Poland.
Jagiellonian University · PLUniversité d'Orléans · FR

Funding

National Science Center 2018/31/B/NZ6/02443National Science Center N N401 547040
6 · The paper itself

Abstract

Many difficult-to-treat human infections related to catheters and other indwelling devices are caused by bacteria residing in biofilms. One of the key properties of microorganisms residing in a biofilm is decreased susceptibility towards antimicrobial agents. Therefore, many different approaches have been researched to destroy or inhibit biofilm production by bacteria. Different iminosugars (IS) were reported to inhibit biofilm formation in

Indexed as

bacterial human pathogensbiofilmiminosugar PDIA

Identifiers

PMID35744740
PMCPMC9228635
OpenAlexW4282933257

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.